Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis

Journal of Internal Medicine

Volumn 248, Issue 1, 2000, Pages 33-41

  Ziegenhagen, M W ^a   Fitschen, J ^a   Martinet, N ^b   Schlaak, M ^a   Muller Quernheim J ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b INSERM   (France)

Author keywords

Disease activity; Sarcoidosis; Soluble TNF receptor

Indexed keywords

RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; INFLAMMATION; MALE; MONITORING; PRIORITY JOURNAL; SARCOIDOSIS; STEROID THERAPY;

ADRENAL CORTEX HORMONES; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MOLECULAR WEIGHT; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS;

EID: 0033926439     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00685.x     Document Type: Article

References (36)

1. 1 Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981; 305: 429-34.
2. 2 Thomas PD, Hunninghake GW. Current concepts of pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135: 747-60.
3. 3 Zissel G, Müller-Quernheim J. Sarcoidosis: historical perspective and immunopathogenesis (part I). Resp Med 1998; 92: 126-39.
4. 4 Müller-Quernheim J. Sarcoidosis: clinical manifestations, staging and therapy (part II). Resp Med 1998; 92: 140-49.
5. 5 Rosenblum GR, Donato NJ. Tumor necrosis factor α: a multifaceted hormone. Crit Rev Immunol 1989; 9: 21-44.
6. 6 Kunkel SL, Chensue SW, Stricter RM, Lynch JP, Remick DG. Cellular and molecular aspects of granulomatous inflammation. Am J Respir Cell Mol Biol 1989; 1: 439-47.
7. 7 Bachwich PR, Lynch JP, Larrick J, Spengler M, Kunkel SL. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol 1986; 125: 421-25.
8. 8 Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42.
9. 9 Müller-Quernheim J, Pfeifer S, Männel D, Strausz J, Ferlinz R. Lung restricted activation of the alveolar macrophage/ monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992; 145: 187-92.
10. 10 Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis. TNFα release of alveolar macrophages and serum level of sIL2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-92.
11. 11 Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990; 87: 3127-31.
12. 12 Loetscher H, Pan YC, Lahm HW et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990; 61: 351-59.
13. 13 Abdolrasulnia R, Shepherd VL. Purification of type I and type II tumor necrosis factor receptors from human lung tissue. Am J Respir Cell Mol Biol 1992; 7: 42-48.
14. 14 Gatanaga T, Hwang CD, Kohr W et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990; 87: 8781-84.
15. 15 Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11 974-80.
16. 16 Andus T, Gross V, Holstege A et al. High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatology 1992; 16: 749-55.
17. 17 Hino T, Nakamura H, Shibata Y, Abe S, Kato S, Tomoike H. Elevated levels of type II soluble tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis. Lung 1997; 175: 187-93.
18. 18 Cope AP, Aderka D, Doherty M et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-69.
19. 19 Aderka D, Wysenbeek A, Engelmann H et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111-20.
20. 20 Denz H, Orth B, Weiss G et al. Serum soluble tumour necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur J Cancer 1993; 29A: 2232-35.
21. 21 Tramper L, Jung W, Dahl G, Diehl V, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 1994; 5(Suppl. 1): 93-96.
22. 22 Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy. J Neuroimmunol 1994; 52: 33-10.
23. 23 Perenboom RM, van Schijndel AC, Beckers P et al. Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seronegative patients with Pneumocystis carinii pneumonia. Eur J Clin Invest 1996; 26: 159-66.
24. 24 Juffermans NP, Verbon A, van Deventer SJ, van Deutekom H, Speelman P, van der Poll T. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am J Respir Crit Care Med 1998; 157: 1328-31.
25. 25 Foley N, Lambert C, McNicol M, Johnson N, Rook GAW. An inhibitor of the toxicity of tumor necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol 1990; 80: 395-99.
26. 26 World Association of Sarcoidosis and Other Granulomatous Disorders. Consensus conference: activity of sarcoidosis. Eur Respir J 1994; 7: 624-27.
27. 27 Hunninghake GW, Gilbert S, Pueringer R et al. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med 1994; 149: 893-98.
28. 28 Costabel U, Bross KJ, Matthys H. The immunoperoxidase slide assay: a new method for demonstration of surface antigens on bronchoalveolar lavage cells. Bull Eur Physiopathol Resp 1985; 21: 381-87.
29. 29 van der Poll T, Jansen J, van Leenen D et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168: 955-60.
30. 30 Nakayama T, Hashimoto S, Amemiya E, Horie T. Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis. Clin Exp Immunol 1996; 104: 318-24.
31. 31 Grunewald J, Shigematsu M, Nagai S et al. T-cell receptor V gene expression in HLA-typed Japanese patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1995; 151: 151-56.
32. 32 Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1601-605.
33. 33 Rochemonteix BG-D, Nicod LP, Bayer J-M. Tumor necrosis factor soluble receptor 75: the principal receptor form released by human alveolar macrophages and monocytes in the presence of Interferon γ. Am J Respir Cell Mol Biol 1996; 14: 279-87.
34. 34 Robinson BWS, McLemore T, Crystal RG. γ Interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75: 1488-95.
35. 35 Tinkle SS, Newman LS. Beryllium-stimulated release of tumor necrosis factor-α, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 1997; 156: 1884-91.
36. 36 Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Müller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Invest Med 1998; 46: 223-31.